Uncategorized
Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject® Trabecular Micro-Bypass System, combined with ca